haematology

---

NIHR Portfolio Studies - open to recruitment

FLAIR: A trial of ibrutinib with rituximab for chronic lymphocytic leukaemia
Principal Investigator: Dr Kathryn Goddard
Sponsor: University of Leeds
This trial is comparing ibrutinib alongside rituximab with fludarabine, cyclophosphamide, rituximab and venetoclax for chronic lymphocytic leukaemia. This trial is for people who haven’t yet had treatment for their chronic lymphocytic leukaemia (CLL).
​

     RADAR (UK-MRA Myeloma XV)
​     Principal Investigator: Dr Arun Alfred
​     Sponsor: University of Leeds
     Comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma

---

  STATIC: Intermittent vs. Continuous treatment strategies in CLL
  Principal Investigator: Dr Kathryn Goddard
  Sponsor: University of Leeds
  ​The primary aim is to assess whether patients with Chronic Lymphocytic Leukaemia (CLL) on long-term                                                              treatment with BTK inhibitor (including ibrutinib) have similar disease control with an intermittent treatment                                                      strategy compared with with standard continuous treatment.

---

     REPAIR-MDS
     Principal Investigator: Dr Arun Alfred
     Co-investigators: Dr Kathryn Goddard, Dr James Taylor & Dr Joe Joseph
     Sponsor: University of Warwick
     This study is to evaluate haematological improvement in patients with low risk Myelodysplastic syndromes               (MDS) by comparing VBaP vs danazol in patients who have either received Erythropoiesis Stimulating Agents                                                     (ESAs) and list response, not responded to ESAs or are deemed unlikely to respond to ESAs. 

---

    SECURE
    Principal Investigator: Dr Arun Alfred
    Co-investigators: Dr Kathryn Goddard, Dr James Taylor & Dr Joe Joseph
    Sponsor: Oxford University Hospitals NHS Foundation Trust 
                                                The study aims to find out more about the role of family history and demographic factors in the development                                                    of MGUS (monoclonal gammopathy of undetermined significance). It will also find out more about the                                                                psychological impact of an MGUS diagnosis and individual quality of life.
    

---

in follow-up (recruitment ended):

​DLBCL: A trial of ibrutinib with chemotherapy and rituximab for a type of diffuse large B cell lymphoma (PHOENIX)
Principal Investigator: Dr Arun Alfred
Sponsor: Celltrion Inc. 
This trial is looking at a drug called ibrutinib for a type of non Hodgkin lymphoma called diffuse large B cell lymphoma (DLBCL). It is for people who have a particular type of DLBCL and who haven’t had any other treatment for their lymphoma.
​

MYELOMA XI
Principal Investigator: Dr Arun Alfred
​Sponsor: University of Leeds
This trial looked at lenalidomide, carfilzomib, bortezomib and vorinostat for people having intensive treatment for newly diagnosed myeloma.
​

Image credit: "A test tube tray containing a number of purple tipped vacutainer tubes. Original image sourced from US Government department: Public Health Image Library, Centers for Disease Control and Prevention. https://www.rawpixel.com/image/2288494/free-photo-image-laboratory-medical-test